N D Kennedy1, G N Lê2, M E Kelly3, T Harding3, K Fadalla4, D C Winter3. 1. Department of Surgery, St Vincent's University Hospital, Elm Park, Dublin 4, Ireland. nllkennedy@gmail.com. 2. The National Institute for Cellular Biotechnology, Dublin City University, Dublin, Ireland. 3. Department of Surgery, St Vincent's University Hospital, Elm Park, Dublin 4, Ireland. 4. Department of Haematology, St Vincent's University Hospital, Elm Park, Dublin 4, Ireland.
Abstract
OBJECTIVES: Splenic marginal zone lymphoma (SMZL) is a rare indolent B-cell lymphoma with variable prognosis. As a result, there is sparse knowledge on the role of splenectomy and best management approaches. We aim to explore management strategies and outcomes amongst the cohort of SMZL patients at our centre. METHOD: A retrospective review of all splenectomies performed at a tertiary referral unit over a 23-year period was assessed. Immunohistochemical and pathological results of splenic samples, bone marrow biopsies, and peripheral blood were compiled. Operative management, surgical, and survival outcomes were assessed. Prognostic stratifications were applied and survival rates were calculated. RESULTS: Eight cases of SMZL from a database of 693 splenectomies were identified. All patients had intermediate/high-risk disease. All patients underwent splenectomy with one patient receiving preoperative rituximab. All patients had progression-free survival and resolution of disease. CONCLUSION: Based on the data obtained, current practice requires defined guidelines and centralised care.
OBJECTIVES:Splenic marginal zone lymphoma (SMZL) is a rare indolent B-cell lymphoma with variable prognosis. As a result, there is sparse knowledge on the role of splenectomy and best management approaches. We aim to explore management strategies and outcomes amongst the cohort of SMZLpatients at our centre. METHOD: A retrospective review of all splenectomies performed at a tertiary referral unit over a 23-year period was assessed. Immunohistochemical and pathological results of splenic samples, bone marrow biopsies, and peripheral blood were compiled. Operative management, surgical, and survival outcomes were assessed. Prognostic stratifications were applied and survival rates were calculated. RESULTS: Eight cases of SMZL from a database of 693 splenectomies were identified. All patients had intermediate/high-risk disease. All patients underwent splenectomy with one patient receiving preoperative rituximab. All patients had progression-free survival and resolution of disease. CONCLUSION: Based on the data obtained, current practice requires defined guidelines and centralised care.
Authors: Apostolia M Tsimberidou; Daniel Catovsky; Ellen Schlette; Susan O'Brien; William G Wierda; Hagop Kantarjian; Guillermo Garcia-Manero; Sijin Wen; Kim-Anh Do; Susan Lerner; Michael J Keating Journal: Cancer Date: 2006-07-01 Impact factor: 6.860